S&P Futures
4,073.00 -17.00 (-0.42%) Dow Futures
34,010.00 -146.00 (-0.43%) Nasdaq Futures
12,107.50 -44.50 (-0.37%) Russell 2000 Futures
1,932.80 -6.60 (-0.34%) Crude Oil
79.13 +0.26 (+0.33%) Gold
1,942.10 -3.20 (-0.16%)
Applied Molecular Transport Inc. (AMTI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.6111 |
| Open | 0.6500 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 3100 |
| Day's Range | 0.6151 - 0.6600 |
| 52 Week Range | 0.3300 - 10.4200 |
| Volume | |
| Avg. Volume | 315,941 |
| Market Cap | 24.248M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4260 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.25 |
- Benzinga
Applied Molecular's Ulcerative Colitis Candidate Fails To Separate From Placebo In Untreated Patients
Applied Molecular Transport Inc (NASDAQ: AMTI) announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). The clinical remission (CR) rate in patients treated with AMT-101 monotherapy was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, which was above the company's baseline assumption for placebo CR rates based on published data in moderate-to-seve
- GlobeNewswire
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s second clinical asset, AMT-126, in UC patients – Exploring strategic partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis – Strong cash position of $76M reported in Q3 2022 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq:
- Simply Wall St.
Aaron VanDevender Is The Independent Director of Applied Molecular Transport Inc. (NASDAQ:AMTI) And They Just Picked Up 239% More Shares
Potential Applied Molecular Transport Inc. ( NASDAQ:AMTI ) shareholders may wish to note that the Independent Director...
